Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 11/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | GCGR | P47871 | 3/20 | 0.42 |
| ▸ | GIPR | P48546 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPRS | Q13332 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083301 | 0.91 | STAT3 (0.83) | STAT3NPC1RAB9APTGESALOX5 | |
| SCHEMBL17083304 | 0.90 | STAT3 (0.75) | STAT3NPC1RAB9APTGESALOX5 | |
| SCHEMBL17083305 | 0.89 | STAT3 (0.79) | STAT3NPC1RAB9APTGESALOX5 | |
| SCHEMBL17077016 | 0.88 | STAT3 (0.81) | STAT3NPC1RAB9APTGESALOX5 | |
| SCHEMBL29811212 | 0.88 | STAT3 (0.72) | STAT3NPC1RAB9APTGESALOX5 | |
| SCHEMBL25404262 | 0.88 | STAT3 (0.72) | STAT3NPC1RAB9APTGESALOX5 | |
| Phosphine SCHEMBL20327612 | 0.87 | STAT3 (0.71) | STAT3NPC1RAB9APTGESALOX5 | |
| SCHEMBL17083327 | 0.87 | STAT3 (0.77) | STAT3NPC1RAB9APTGESALOX5 | |
| Phosphine SCHEMBL19618939 | 0.87 | STAT3 (0.73) | STAT3NPC1RAB9APTGESALOX5 | |
| SCHEMBL17076949 | 0.86 | STAT3 (1.00) | STAT3NPC1RAB9APTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | STAT3 3/4885NPC1 4238/4885RAB9A 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.